secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2024-02-06T23:59:59+00:00
Accession:  0001493152-24-005046
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics enters $14M registered direct offering at $1.04/share
-------------------------------------------------------------------------------

- Sale of 13,461,540 common shares at $1.04 each; gross proceeds of $14.0M.
- Broadwood Partners (affiliated with director Neal Bradsher) to buy 6,730,770 shares.
- Director Don M. Bailey to buy approximately 100,000 shares in the offering.
- Closing expected on or about February 8, 2024, subject to customary conditions.
- Proceeds to fund clinical trials, R&D, G&A, and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000149315224005046/0001493152-24-005046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000149315224005046/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-005046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer